Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple block test detect 'Silent' brain fog in liver disease?

NCT ID NCT06619106

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a new cognitive test using building blocks to quickly screen for minimal hepatic encephalopathy (MHE), a subtle brain complication in people with liver disease. Researchers will compare the test's accuracy against standard methods in 100 adults with liver fibrosis, cirrhosis, or porto-systemic shunts. If proven reliable, it could offer a faster, simpler way to diagnose MHE.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cognitive test using building blocks
What this could lead to
If successful, this could provide a quick, reliable screening tool for minimal hepatic encephalopathy, helping doctors diagnose it earlier and more accurately.
What could go wrong
This is a small pilot study (100 participants) testing a new tool against existing tests. It may not prove accurate enough or may not work in broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with liver cirrhosis or portosystemic shunts with suspicion of minimal hepatic encephalopathy

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 70 years * Hepatic pathology (fibrosis, cirrhosis, porto-systemic shunts) * Evaluation at BLIPS clinic (neuropsychological assessment, MRI, EEG and blood sample with ammonia) Exclusion Criteria: * Opposition to participating in the study * Not being affiliated with French healthcare system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic pathology (fibrosis, cirrhosis, porto systemic shunts) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fibrosis hepatic encephalopathy liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic pathology (fibrosis, cirrhosis, porto systemic shunts)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hepato-gastro-enterology department, Pitié Salpêtrière hospital

    RECRUITING

    Paris, 75013, France